Jeremy Graff is Senior Vice President, Head of Rare Disease Franchise at Biogen. After joining the company, Jeremy led the transformation from a single maturing therapy to a broad Rare Disease franchise with three marketed products, multiple assets in Phase 3, and an expansive R&D portfolio across an array of neuromuscular and neurodevelopmental genetic diseases. This was accomplished through both organic growth and transactions leveraging external innovation.

Prior to joining Biogen, Jeremy was Group Vice President and General Manager, Rheumatology Business Unit at Horizon Therapeutics where his accomplishments include leading the strategic relaunch of a Rare Disease therapy which contributed substantial value creation for Horizon prior to its acquisition by Amgen. Before joining Horizon, Jeremy advanced through multiple leadership roles of increasing responsibility at AbbVie and Abbott Laboratories over 17 years, including through the formative launch years of its Immunology Franchise and the expansion of its Women's Health portfolio.

Jeremy holds a bachelor's degree in Engineering from Cornell University and an MBA from The University of Chicago Booth School of Business.